Navigation Links
Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
Date:12/12/2007

Company's ability to build and maintain successful partnerships, patient recruitment expertise and its global reach cited as reasons for selection

CINCINNATI, Dec. 12 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced it was named "Best CRO" at the Scrip Awards held Dec. 4 in London. Kendle was selected from among leading global CROs by a distinguished panel of pharmaceutical industry executives. The annual awards competition, organized by Scrip World Pharmaceutical News, a leading provider of news and analysis for the global biopharmaceutical industry, is designed to recognize new standards of excellence and celebrate achievements that reflect cutting-edge science and the intellectually exciting and socially rewarding nature of the industry. This is the second year in a row Kendle has received the "Best CRO Award."

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

"Kendle is honored to be recognized once again by the Scrip expert panel as 'Best CRO'," noted Candace Kendle, PharmD, Chairman and Chief Executive Officer. "In a service business it's all about people, and at Kendle our associates offer exceptional qualities that make a real difference to our customers."

According to Scrip World Pharmaceutical News, "The judges felt that among Kendle's strengths are its ability to build and maintain successful partnerships, its global reach, patient recruitment expertise, its skills in core therapeutic areas as well as niche areas and its extensive pregnancy registry."

Selection criteria for the award included performance across multip
'/>"/>

SOURCE Kendle International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
11. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ) ... and investor conference presentations and third,quarter 2008 earnings ... Meeting in Washington D.C. from,October 25 through October ... data in posters and an oral presentation pertaining ...
... Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), ... viral,infections, today announced that updated preliminary data from the first,stage of ...
... product ... development for NewCardio, SANTA CLARA, Calif., ... diagnostic and services company, today,announced Dorin Panescu, PhD, has agreed ... Research and Development, effective,October 20. Dr. Panescu joins NewCardio from ...
Cached Biology Technology:Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 2Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4Dorin Panescu Named NewCardio's Chief Technical Officer 2Dorin Panescu Named NewCardio's Chief Technical Officer 3Dorin Panescu Named NewCardio's Chief Technical Officer 4
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... Neuherberg, February 10., 2010. Eczema in early childhood ... This is a key finding of a prospective birth ... contributed. In cooperation with colleagues of Ludwig-Maximilians-Universitt (LMU), Technische ... this study followed 5,991 children who were born between ...
... by a top ecological,forecaster says it is harder than ... systems will occur -- a worrisome,finding for scientists trying ... into an irreparable global disaster. "Many scientists are ... natural systems, in hopes of forestalling those changes,or improving ...
... off attacks by Hessian fly larvae by essentially destroying the ... a study by Purdue University and the U.S. Department of ... intestines - were observed in three different feeding situations. Larvae ... given nothing to eat showed no damage to the midgut, ...
Cached Biology News:Eczema in early childhood and psychological problems 2New UC Davis study: Climate 'tipping points' may arrive without warning, says top forecaster 2Resistant wheat goes for the gut to protect against Hessian flies 2